Big new study in pediatric and young adult acute myeloid leukemia warns against ‘trickle-down therapeutics’
Dec. 11, 2017
| By Susan Keown / Fred Hutch News Service
Researchers found key differences between the molecular signatures of AML in patients of different ages: So why should we keep assuming that therapies developed for the elderly will work for the young?
An immunotherapy technology developed by Dr. Brian Till with Dr. Oliver Press at Fred Hutchinson Cancer Research Center has been licensed by Mustang Bio Inc., a subsidiary of the biopharmaceutical company Fortress Biotech Inc. The exclusive, worldwide license, announced Sept. 14 by Mustang Bio, will allow a new type of CAR (chimeric antigen receptor) T-cell therapy to be tested in a clinical trial as a treatment for B-cell non-Hodgkin lymphomas. The novel immunotherapy targets CD20, a protein marker on cancer cells in lymphoma.
Dr. Filippo Milano and colleagues in the Cord Blood Program at Fred Hutch have received funding from the Robert J. Kleberg, Jr. and Helen C. Kleberg Foundation to support a clinical trial to improve the use of umbilical cord blood as a treatment for leukemia ... and more good news at Fred Hutch.
Fred Hutch is proud to be an Equal Opportunity and VEVRAA Employer. We are committed to cultivating a workplace in which diverse perspectives and experiences are welcomed and respected. We do not discriminate on the basis of race, color, religion, creed, ancestry, national origin, sex, age, disability, marital or veteran status, sexual orientation, gender identity, political ideology, or membership in any other legally protected class. We are an Affirmative Action employer. We encourage individuals with diverse backgrounds to apply and desire priority referrals of protected veterans. Read the EEO is the Law poster here.